Fusion Antibodies
↗Belfast, Northern Ireland, United Kingdom
Fusion Antibodies Plc is a Belfast-based Contract Research Organization (CRO) established in 2001 as a spinout from Queen's University Belfast. The company specializes in antibody discovery, engineering, development, and manufacturing services for therapeutic and diagnostic applications, particularly in cancer and infectious disease therapeutics. Fusion operates as a revenue-generating, profitable CRO providing integrated end-to-end antibody engineering services including antibody generation, sequencing, humanization, affinity maturation, recombinant protein expression, and cGMP-scale manufacturing. The company serves an international blue-chip client base including 8 of the top 10 global pharmaceutical companies by revenue, having guided approximately 15 of their clients' projects through to clinical development stages, with some advancing as far as Phase II.
CLASSIFICATION
Company Type:CRO
Therapeutic Areas:
Industry:Pharmaceuticals|Biotechnology
Sub-Industry:Contract Research Organization (CRO)|Antibody Engineering|Biopharmaceutical Services
SIZE & FINANCIALS
Employees:1-50
Revenue:£1-2M
Founded:2001
Ownership:public
Status:operating
FUNDING
Stage:Public company
STOCK
Exchange:LSE (London Stock Exchange)
Ticker:FAB
Market Cap:£16.20m
PIPELINE
Stage:Discovery|Preclinical|Clinical (clients' projects)
Lead Drug Stage:N/A - CRO provides services to clients; does not develop own pipeline
Modalities:Monoclonal Antibodies, Antibody Humanization, Affinity Maturation, Recombinant Proteins, Stable Cell Lines
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:National Cancer Institute (NCI) - OptiMAL® validation collaboration, Celonic AG (Switzerland) - CMO partnership for cell line development, BizCom Japan - Japanese market distributor, Protein Alternatives - Partnership announced, Queen's University Belfast - Academic collaboration and grant consortium, Future Medicines Institute (FMI) - Research consortium for Northern Ireland Precision Biomarkers and Therapeutics
COMPETITION
Position:Niche Player
Competitors:Metrum Research Group, Clovis Oncology, ArcherDX, Absolute Antibody, Creative Biolabs, Exonbio, Genmab, Ablexis
LEADERSHIP
Key Executives:
Adrian Kinkaid, PhD - Chief Executive Officer
Richard Buick, PhD - Chief Scientific Officer
James Fair - Chief Financial Officer
Simon Douglas - Non-Executive Chairman
Scientific Founders:Originally spun out from Queen's University Belfast in 2001
Board Members:Simon Douglas (Non-Executive Chairman), Adrian Kinkaid, PhD (Chief Executive Officer), Richard Buick, PhD (Chief Scientific Officer), James Fair (Chief Financial Officer), Colin Walsh (Non-Executive Director, Audit Committee Chair), Sonya Ferguson (Non-Executive Director), Matthew Baker (Non-Executive Director)
LINKS
Website:fusionantibodies.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Fusion Antibodies. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.